Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US8342033094
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG0024L5B86
SLNO
Soleno Therapeutics Inc
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Soleno Therapeutics Inc
ISIN
US8342033094
TICKER
SLNO
MIC
XNAS
REUTERS
SLNO.OQ
BLOOMBERG
SLNO US
Sun, 26.04.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - April 26, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Soleno Therapeutics, Inc. (NASDAQ: SLNO) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged viola...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sun, 26.04.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - April 25, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, inclusive, (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline. SO WHAT: If you purchase...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 25.04.2026       Soleno Therapeutics
US8342033094

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Soleno between March 26, 2025 and November 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 25.04.2026       Soleno Therapeutics
US8342033094

NEW YORK and NEW ORLEANS, April 24, 2026 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NasdaqCM: SLNO) of a class action securities lawsuit.   CLASS DEFINITION: The...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 24.04.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - April 24, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, inclusive, (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline. SO WHAT: If you purchase...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 24.04.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - April 24, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Soleno Therapeutics, Inc. (NASDAQ: SLNO) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged viola...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 23.04.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - April 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, inclusive, (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline. SO WHAT: If you purchase...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 23.04.2026       Soleno Therapeutics
US8342033094

SAN FRANCISCO, April 23, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman reminds investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO) of the pending securities class action and the upcoming May 5, 2026 lead plaintiff deadline. The firm urges investors who purchased Soleno common stock between March 26, 2025, and November 4...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 23.04.2026       Soleno Therapeutics
US8342033094

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Soleno between March 26, 2025 and November 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 23.04.2026       Soleno Therapeutics
US8342033094

Important Notice Regarding Alleged DCCR Safety Data MisrepresentationsNEW YORK, April 23, 2026 /PRNewswire/ -- SueWallSt notifies investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO) that a class action lawsuit has been filed on behalf of shareholders who purchased securities between March 26, 2025 and November 4, 2025. Find out if you qualify to...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Thu, 23.04.2026       Soleno Therapeutics
US8342033094

NEW YORK, April 22, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, both dates in...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 22.04.2026       Soleno Therapeutics
US8342033094

LOS ANGELES, April 22, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO)....
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 22.04.2026       Soleno Therapeutics
US8342033094

From Optimism to Disillusionment: How Investor Sentiment ShiftedNEW YORK, April 22, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP provides context on the dramatic shift in investor sentiment surrounding Soleno Therapeutics, Inc. (NASDAQ: SLNO) and its only commercial product, VYKAT XR (diazoxide choline extended-release tablets, or DCCR), approve...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 22.04.2026       Soleno Therapeutics
US8342033094

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Soleno between March 26, 2025 and November 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Jos...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 22.04.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - April 21, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, inclusive, (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline. SO WHAT: If you purchase...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.04.2026       Soleno Therapeutics
US8342033094

SAN FRANCISCO, April 21, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman reminds investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO) of the pending securities class action and the upcoming May 5, 2026 lead plaintiff deadline. The firm urges investors who purchased Soleno common stock between March 26, 2025, and November 4...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.04.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - April 21, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Soleno Therapeutics, Inc. (NASDAQ: SLNO) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged viola...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.04.2026       Soleno Therapeutics
US8342033094

Bernstein Liebhard LLP:Do you, or did you, own shares of Soleno Therapeutics, Inc. (NASDAQ: SLNO)?Did you purchase your shares between March 26, 2025 and August 4, 2025, inclusive?Did you lose money in your investment in Soleno Therapeutics, Inc.?Do you want to discuss your rights?New York, New York--(Newsfile Corp. - April 21, 2026) - Bernstein Li...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.04.2026       Soleno Therapeutics
US8342033094

NEW YORK, April 21, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Soleno Therapeutics, Inc. (NASDAQ: SLNO). Shareholders who purchased shares of SLNO during the class period listed are encourag...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 20.04.2026       Soleno Therapeutics
US8342033094

Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Soleno Therapeutics, Inc. (NASDAQ: SLNO) common stock between March 26, 2025 and November 4, 2025. Soleno is a pharmaceutical company focused on developing therapies for rare diseases. The Company’s only commercial product...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Mon, 20.04.2026       Soleno Therapeutics
US8342033094

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Soleno between March 26, 2025 and November 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 20.04.2026       Soleno Therapeutics
US8342033094

LOS ANGELES, April 20, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Soleno Therapeutics, Inc. ("Soleno" or "the Company") (NASDAQ: SLNO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Share...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 20.04.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - April 19, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If you pu...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sun, 19.04.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - April 19, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Soleno Therapeutics, Inc. (NASDAQ: SLNO) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged viola...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sun, 19.04.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - April 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If y...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 18.04.2026       Soleno Therapeutics
US8342033094

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Soleno between March 26, 2025 and November 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 18.04.2026       Soleno Therapeutics
US8342033094

NEW ORLEANS, April 17, 2026 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 5, 2026 to file lead plaintiff applications in a securities class action lawsuit against Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NasdaqCM: SLNO), if they purchased or otherwise acquired the Comp...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 18.04.2026       Soleno Therapeutics
US8342033094

San Diego, California--(Newsfile Corp. - April 17, 2026) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Soleno Therapeutics, Inc. (NASDAQ: SLNO) common stock between March 26, 2025 and November 4, 2025, inclusive (the "Class Period"), have until Tuesday, May 5, 2026 to seek appointment as lead plaintiff of the S...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 18.04.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - April 17, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If y...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 17.04.2026       Soleno Therapeutics
US8342033094

NEW YORK, April 17, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, both dates in...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 17.04.2026       Soleno Therapeutics
US8342033094

BENSALEM, Pa., April 17, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN SOLENO THERAPEUTICS, INC. (S...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 17.04.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - April 17, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Soleno Therapeutics, Inc. (NASDAQ: SLNO) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged viola...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 17.04.2026       Soleno Therapeutics
US8342033094

SAN FRANCISCO, April 17, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman reminds investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO) of the pending securities class action and the upcoming May 5, 2026 lead plaintiff deadline. The firm urges investors who purchased Soleno common stock between March 26, 2025, and November 4...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 17.04.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - April 16, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If you pu...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 16.04.2026       Soleno Therapeutics
US8342033094

NEW YORK, April 16, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-ma...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 16.04.2026       Soleno Therapeutics
US8342033094

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Soleno between March 26, 2025 and November 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Jos...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 16.04.2026       Soleno Therapeutics
US8342033094

Key Dates and Disclosure Events Shareholders Need to Know NEW YORK, April 16, 2026 /PRNewswire/ -- SueWallSt encourages investors who suffered losses in Soleno Therapeutics, Inc. (NASDAQ: SLNO) to contact the firm. Those who purchased SLNO securities between March 26, 2025 and November 4, 2025 may be entitled to recover damages.  Find out if you...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 15.04.2026       Soleno Therapeutics
US8342033094

LOS ANGELES, April 15, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO) have opportunity to lead the securities fraud class action lawsuit....
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 15.04.2026       Soleno Therapeutics
US8342033094

SAN FRANCISCO, April 15, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman reminds investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO) of the pending securities class action and the upcoming May 5, 2026 lead plaintiff deadline. The firm urges investors who purchased Soleno common stock between March 26, 2025, and November 4...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 15.04.2026       Soleno Therapeutics
US8342033094

Alert: Claims Focus on Alleged Misrepresentations About Clinical Trial Integrity and Drug SafetyNEW YORK, April 15, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of Soleno Therapeutics, Inc. (NASDAQ: SLNO) securities of a pending securities class action....
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 15.04.2026       Soleno Therapeutics
US8342033094

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers.Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basi...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 15.04.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - April 14, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If you pu...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 14.04.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - April 14, 2026) - Bernstein Liebhard LLP:Do you, or did you, own shares of Soleno Therapeutics, Inc. (NASDAQ: SLNO)?Did you purchase your shares between March 26, 2025 and August 4, 2025, inclusive?Did you lose money in your investment in Soleno Therapeutics, Inc.?Do you want to discuss your rights?Bernstein Li...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 14.04.2026       Soleno Therapeutics
US8342033094

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Soleno between March 26, 2025 and November 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 14.04.2026       Soleno Therapeutics
US8342033094

NEW YORK, April 14, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Soleno Therapeutics, Inc. (NASDAQ: SLNO). Shareholders who purchased shares of SLNO during the class period listed are encourag...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 14.04.2026       Soleno Therapeutics
US8342033094

SAN FRANCISCO, April 13, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman reminds investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO) of the pending securities class action and the upcoming May 5, 2026 lead plaintiff deadline. The firm urges investors who purchased Soleno common stock between March 26, 2025, and November 4...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 13.04.2026       Soleno Therapeutics
US8342033094

LOS ANGELES, April 13, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Soleno Therapeutics, Inc. ("Soleno" or "the Company") (NASDAQ: SLNO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Share...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 13.04.2026       Soleno Therapeutics
US8342033094

LOS ANGELES, April 13, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Soleno Therapeutics, Inc. ("Soleno" or "the Company") (NASDAQ: SLNO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sun, 12.04.2026       Soleno Therapeutics
US8342033094

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Soleno between March 26, 2025 and November 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Jos...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sun, 12.04.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - April 11, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If y...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink